SEC EDGARAUG 201 min read$CAH

Scherer Mary C. sold $546K of CAH

Scherer Mary C. (Chief Accounting Officer) sold 2,302 shares of CARDINAL HEALTH INC (CAH) at an average of $237.39 ($237.39–$237.40, $0.55M total) across 2 trades on 2026-08-19.

Original reporting

SEC EDGAR · Scherer Mary C.

Published Aug 20, 2026, 8:10 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 20, 2026, 8:16 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$CAH

Neutral

medium confidence

Mentioned

$CAH

Relevance

5/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CAHNeutralLow

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for analysts.

Market read

Small insider sale; limited trading relevance.

What to watch

No 10b5‑1 plan; timing may be personal rather than strategic.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑08‑19

Background

Form 4 filings disclose insider trades; investors monitor them for signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHNeutralMedium confidence

Context

Chief Accounting Officer Mary C. Scherer sold 2,302 shares of Cardinal Health for $546K on 2026-08-19.

Expected impact

Potential slight downward pressure, unlikely to move price materially.

Evidence & confidence

The $546K sale represents a tiny fraction of Cardinal Health's float; market reaction is typically muted for such small insider transactions.

Market effects

Sector

Minimal impact on healthcare distribution sector.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be unrelated to confidence; could be tax or portfolio rebalancing.

Key entities

Company
Cardinal Health Inc.
U.S. health services and products distributor.
Person
Mary C. Scherer
Chief Accounting Officer of Cardinal Health.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 20

$CAHMed

Hollar Jason M. sold $29.4M of CAH

Hollar Jason M. (Chief Executive Officer) sold 124,529 shares of CARDINAL HEALTH INC (CAH) at an average of $235.89 ($233.22–$237.88, $29.38M total) across 10 trades over 2026-08-18 to 2026-08-19.

SEC EDGAR1 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min